2024-03-22 11:49:09 ET
Summary
- Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns.
- FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales of over $2 billion.
- Despite positive developments, caution remains due to slow QUVIVIQ sales and the need for additional cost savings.
Here at the Lab, following the exciting news on Idorsia ( IDRSF ), we are back to comment on the company equity story. Idorsia is a Switzerland-based biopharmaceutical player specializing in small molecule discovery. The company has a diverse pipeline and targets several diseases, including chronic insomnia, systemic lupus erythematosus, and resistant hypertension....
Read the full article on Seeking Alpha
For further details see:
Idorsia: Aprocitentan Approval Is A Vital News